TY - JOUR
T1 - Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
AU - Quintás-Cardama, Alfonso
AU - Cortes, Jorge
PY - 2008/7/15
Y1 - 2008/7/15
N2 - Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease. Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib. Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid. This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket. To expedite the identification of strategies to override the resistance imposed by the T3151 mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1. Recent insights gained regarding the structural biology of T315I have led to the development of a variety of compounds against this mutant. We herein summarize the most clinically promising anti-T3151 therapies.
AB - Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease. Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib. Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid. This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket. To expedite the identification of strategies to override the resistance imposed by the T3151 mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1. Recent insights gained regarding the structural biology of T315I have led to the development of a variety of compounds against this mutant. We herein summarize the most clinically promising anti-T3151 therapies.
UR - http://www.scopus.com/inward/record.url?scp=51649120694&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51649120694&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-08-0117
DO - 10.1158/1078-0432.CCR-08-0117
M3 - Review article
C2 - 18628453
AN - SCOPUS:51649120694
SN - 1078-0432
VL - 14
SP - 4392
EP - 4399
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 14
ER -